+

WO2003013488A3 - Methods and compositions for inhibiting rad51 - Google Patents

Methods and compositions for inhibiting rad51 Download PDF

Info

Publication number
WO2003013488A3
WO2003013488A3 PCT/US2001/024986 US0124986W WO03013488A3 WO 2003013488 A3 WO2003013488 A3 WO 2003013488A3 US 0124986 W US0124986 W US 0124986W WO 03013488 A3 WO03013488 A3 WO 03013488A3
Authority
WO
WIPO (PCT)
Prior art keywords
pnp
aif4
group
tdp
gdp
Prior art date
Application number
PCT/US2001/024986
Other languages
French (fr)
Other versions
WO2003013488A2 (en
Inventor
Gurucharan Reddy
David A Zarling
Original Assignee
Pangene Corporation
Gurucharan Reddy
David A Zarling
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pangene Corporation, Gurucharan Reddy, David A Zarling filed Critical Pangene Corporation
Priority to PCT/US2001/024986 priority Critical patent/WO2003013488A2/en
Priority to AU2001283226A priority patent/AU2001283226A1/en
Publication of WO2003013488A2 publication Critical patent/WO2003013488A2/en
Publication of WO2003013488A3 publication Critical patent/WO2003013488A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Described herein are methods for inhibiting Rad51 activity, especially in cancerous cells by the administration of a Rad51 inhibitor. The Rad51 inhibitors described herein are small molecules, preferably smaller than 4kd, including nucelotide diphsophates (selected from the group consisting of ADP, GDP, CDP, UDP and TDP), nucleotide diphosphate complexed with aluminium fluoride (selected from the group consisting of ADP.AIF4, GDP.AIF4, CDP.AIF4, UDP.AIF4 and TDP.AIF4), nucleoside analogues (selected from the group consisiting of ATPyS, GTPyS, UTPyS, CTPyS, TTPyS, ADPyS, GDPyS, UDPyS, CDPyS, TDPyS, AMPyS, GMPyS, UMPyS, CMPyS, TMPyS, ATP-PNP, GTP-PNP, UTP-PNP, CTP-PNP, TTP-PNP, ADP-PNP, GDP-PNP, UDP, PNP, CDP-PNP, TDP-PNP, AMP-PNP, GMP-PNP, UMP-PNP, CMP-PNP and TMP-PNP), DNA minor groove binding agents (selected from the group consisting of distamycin, netropsin, bisbenzimidazole and actinomycin), xanthine derivatives (preferably caffeine), or peptides.
PCT/US2001/024986 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51 WO2003013488A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US2001/024986 WO2003013488A2 (en) 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51
AU2001283226A AU2001283226A1 (en) 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2001/024986 WO2003013488A2 (en) 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51

Publications (2)

Publication Number Publication Date
WO2003013488A2 WO2003013488A2 (en) 2003-02-20
WO2003013488A3 true WO2003013488A3 (en) 2003-08-21

Family

ID=21742766

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024986 WO2003013488A2 (en) 2001-08-09 2001-08-09 Methods and compositions for inhibiting rad51

Country Status (2)

Country Link
AU (1) AU2001283226A1 (en)
WO (1) WO2003013488A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597949B2 (en) 2007-07-28 2013-12-03 The University Of Chicago Methods and compositions for modulating RAD51 and homologous recombination
CA2909383C (en) 2012-04-12 2020-11-10 University Of Saskatchewan Phthalocyanine compounds useful as reca inhibitors and methods of using same
WO2014085545A1 (en) 2012-11-30 2014-06-05 The University Of Chicago Methods and compositions involving rad51 inhibitors
JP2015051946A (en) * 2013-09-06 2015-03-19 学校法人早稲田大学 Compound having cell proliferation inhibitory activity, pharmaceutical composition and screening method
BR112018074472A2 (en) 2016-05-27 2019-03-19 Synthex, Inc. protein interfaces
WO2019104244A1 (en) 2017-11-22 2019-05-31 Synthex, Inc. Peptides for inhibiting rad51

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020030A2 (en) * 1996-11-05 1998-05-14 Lexicon Genetics Incorporated DISRUPTION OF THE MAMMALIAN Rad51 PROTEIN AND DISRUPTION OF PROTEINS THAT ASSOCIATE WITH MAMMALIAN Rad51 FOR HINDERING CELL PROLIFERATION
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
EP1006185A1 (en) * 1998-10-06 2000-06-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Tissue-specific splice variant of recombination-repair gene rad51b associated with t(12;14)-uterine leiomyomas
WO2000047231A2 (en) * 1999-02-10 2000-08-17 Pangene Corporation Novel antisense inhibition of rad51
WO2001011369A1 (en) * 1999-08-10 2001-02-15 Pangene Corporation Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998020030A2 (en) * 1996-11-05 1998-05-14 Lexicon Genetics Incorporated DISRUPTION OF THE MAMMALIAN Rad51 PROTEIN AND DISRUPTION OF PROTEINS THAT ASSOCIATE WITH MAMMALIAN Rad51 FOR HINDERING CELL PROLIFERATION
WO1998034118A1 (en) * 1997-01-30 1998-08-06 Yale University Diagnostic methods and compositions based on the distribution of rad51
EP1006185A1 (en) * 1998-10-06 2000-06-07 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Tissue-specific splice variant of recombination-repair gene rad51b associated with t(12;14)-uterine leiomyomas
WO2000047231A2 (en) * 1999-02-10 2000-08-17 Pangene Corporation Novel antisense inhibition of rad51
WO2001011369A1 (en) * 1999-08-10 2001-02-15 Pangene Corporation Cancer treatments and diagnostics utilizing rad51 related molecules and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUCHHOP SABINE ET AL: "Interaction of p53 with the human Rad51 protein", NUCLEIC ACIDS RESEARCH, IRL PRESS LTD., OXFORD, GB, vol. 25, no. 19, 1997, pages 3868 - 3874, XP002146663, ISSN: 0305-1048 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor

Also Published As

Publication number Publication date
WO2003013488A2 (en) 2003-02-20
AU2001283226A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
WO2003013488A3 (en) Methods and compositions for inhibiting rad51
MY135909A (en) Treatment of pulmonary hypertension
BRPI0616630B8 (en) substituted pyrazole compounds
WO2005002576A3 (en) Imidazole derivatives and their use as protein kinases inhibitors
MXPA03004037A (en) Indolylmaleimide derivatives as protein kinase c inhibitors.
WO2003081210A3 (en) Identification of kinase inhibitors
AU2003303502A1 (en) Computer systems and methods for associating genes with traits using cross species data
WO2005035003A3 (en) Compositions and methods for increasing drug efficiency
AU2002341942A8 (en) Sugar modified nucleosides as viral replication inhibitors
IL167088A (en) Pyrazolopyrimidine derivatives as cyclin dependent kinase inhibitors
AU2003221801A8 (en) Compositions selective for adenosine diphosphate and methods of using same
AU2002359732A1 (en) Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies
AU2002239277A1 (en) Adenine based inhibitors of adenylyl cyclase, pharmaceutical compositions and method of use thereof
WO2006065597A3 (en) Id-tag complexes, arrays, and methods of use thereof
WO2003099194A3 (en) Pharmaceutical combination of pde5 inhibitors with ace inhibitors
WO2003106625A3 (en) Hammerhead ribozymes
AU2003213005A1 (en) RNA INTERFERENCE MEDIATED INHIBITION OF PROTEIN KINASE C ALPHA (PKC-ALPHA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2001051651A3 (en) High expression and production of high-specific activity recombinant s-adenosyl homocysteinase (sahh) and improved assays for s-adenosylmethionine (sam)
AUPS251502A0 (en) Protein kinase inhibitors
AU2003300124A1 (en) Novel nucleoside transport inhibitors
AP2005003215A0 (en) Storing and detecting nucleic acid administered toa solid carrier.
WO2003099228A3 (en) Compositions and processes for inhibiting gene expression using polynucleotides
AU2003282564A1 (en) Gene profiling of single or multiple cells
IL165976A0 (en) Sulphonylpiperidine derivatives containing an arylor heteroaryl group for use as matrix metalloprot einase inhibitors
WO2003042369A3 (en) Cellular kinase targets and inhibitors, and methods for their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载